The size of the Psychiatry Therapies Market in Europe is estimated to hike at a robust CAGR from 2020 to 2025.
Psychiatry Therapies cam be defined as therapeutic interaction processes between patients and trained psychiatric professionals in order to treat psychological problems of patients. Psychiatric therapies involve the treatment of mental and emotional disorders and behaviour disturbance by using psychological therapies and techniques. These psychiatry therapies are planned to modify the behaviour of a patient and provide relief from disorders.
Psychiatry therapies fundamentally rely on establishing relationship between psychiatry therapist and patients for developing a patient’s behavioural insights. Psychiatry therapist use electrical shocks or psychological drugs to change the emotions of their patients. Verbal and Non-verbal communication with the patient and other physical intervention is also beneficial in the treatment of psychiatry patients. In addition, adjuvant therapies like occupational therapies and music therapies are also helpful during the treatment. All of these therapies aim to improve the well-being of patients by employing range of relationships and psychological techniques.
The key driving factor of Europe psychiatry therapies market is the rising prevalence of mental and emotional health issues. This rising incidence of psychological ailments is going to rise the demand for treatment, resulting in the growth of this market. Rising stress condition, emotional, physical and mental pressure among population is also increasing the demand of psychiatry therapies and resulting in the growth of psychiatry therapies market. In addition, rising chronic diseases and anxiety disorders will further drive the market of psychiatry therapies.
However, the market is constrained by factors like strict regulations for practising psychotherapy by various governments.
This research report on the Europe Psychiatry Therapies Market has been segmented and sub-segmented into the following categories:
Regionally, Europe has the second largest market for psychiatry therapy in the world by share. Factors such as growing prevalence of psychological ailments and stress levels is expected to result in the growth of this market.
Companies dominating the European Psychiatry Therapies market are Astrazeneca, Universal Health Services Inc., Johnson & Johnson, Pfizer, GlaxoSmithKline, Eli Lilly, Bristol-Meyer Squibb, Wyeth, Astellas Pharma Inc. and others.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Type
5.1.1 Social Psychology
5.1.2 Abnormal Psychology
5.1.3 Biological Psychology
5.1.4 Other Types
5.1.5 Y-o-Y Growth Analysis, By Type
5.1.6 Market Attractiveness Analysis, By Type
5.1.7 Market Share Analysis, By Type
5.2 Type of Medication
5.2.1 Antidepressants
5.2.2 Antipsychotics
5.2.3 Depressants
5.2.4 Anxiolytics
5.2.5 Mood Stabilisers
5.2.6 Stimulants
5.2.7 Other Types of Medication
5.2.8 Y-o-Y Growth Analysis, By Type of Medication
5.2.9 Market Attractiveness Analysis, By Type of Medication
5.2.10 Market Share Analysis, By Type of Medication
5.3 Type of Therapy
5.3.1 Counselling
5.3.2 Cognitive Behavioural Therapy
5.3.3 Family Therapy
5.3.4 Psychotherapy
5.3.5 Group Therapy
5.3.6 Relationship Counselling
5.3.7 Interpersonal Therapy
5.3.8 Behavioural Activation
5.3.9 Other Types of Therapy
5.3.10 Y-o-Y Growth Analysis, By Type of Therapy
5.3.11 Market Attractiveness Analysis, By Type of Therapy
5.3.12 Market Share Analysis, By Type of Therapy
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Type
6.1.3.2 By Type of Medication
6.1.3.3 By Type of Therapy
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Type
6.1.4.2 By Type of Medication
6.1.4.3 By Type of Therapy
6.1.5 Market Share Analysis
6.1.5.1 By Type
6.1.5.2 By Type of Medication
6.1.5.3 By Type of Therapy
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Astrazeneca
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Universal Health Services Inc.
8.3 Johnson & Johnson
8.4 Pfizer
8.5 GlaxoSmithKline
8.6 Eli Lilly
8.7 Bristol-Meyer Squibb
8.8 Wyeth
8.9 Astellas Pharma Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
